Oxaliplatin-induced type II hypersensitivity in colorectal cancer: a cohort study on clinical presentation, diagnosis, and management
OXL-induced II-HSRs are rare but pose diagnostic and management challenges. This study shows the importance of early identification, the potential role of DDAbs testing, and the feasibility of re-exposure under controlled conditions in selected patients.
Authors
- Jose Carlos J C Ruffinelli
- Paula Vázquez‐Revuelta (ORCID: https://orcid.org/0000-0002-1595-9180)
- Ramón Lleonart
- Ricardo Madrigal‐Burgaleta (ORCID: https://orcid.org/0000-0002-3358-3578)
- Ana Coloma (ORCID: https://orcid.org/0000-0002-1773-9560)
- Enric Casanovas
Institutions
- St Bartholomew's Hospital (GB)
- Barts Health NHS Trust (GB)
- Bellvitge University Hospital (ES)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Institut Català d'Oncologia (ES)
- Banc de Sang i Teixits (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fphar.2025.1605690
- Citations
- 1
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 1.39